GeroNova Research is setting the industry standards for research, analysis and lipoic acid products.
Pharmaceutical Composition Comprising an Enantiomer of Lipoamide and Derivatives Thereof and Methods of Use.
US Patent: 9,351, 956 B1 (May 31, 2016). Link to pdf.
R-(+)-Lipoamide has been shown to be more potent than R-(+)-lipoic acid in several model hepatic systems. In vivo plasma analysis of p.o. and i.v. administered lipoamide reveals only lipoic acid in circulation even at the first sampling time point thus highlighting the limitations of extrapolating in vitro studies to living organisms. Despite this apparent limitation, lipoamide has been detected at therapeutically useful levels in liver for an hour before the amide is hydrolyzed back to lipoic acid and numerous metabolites. Our signal transduction studies have demonstrated this time course is sufficient to activate cellular signaling pathways responsible for upregulation of early response genes associated with hepatic protection, detoxification and liver regeneration. Currently the primary treatment protocol for liver failure is transplant. Therefore further research is indicated to test the effects of lipoamide and other amide derivatives for the ability to regenerate damaged hepatic tissues. If you are interested in developing lipoamide and derivatives as a pharmaceutical agent or a dietary supplement, please contact us.
a. Klinik für Medizinische Rehabilitation und Geriatrie der Henriettenstiftung,
b. Dept. of Pharmacology, School of Medicine, University of Western Sydney,
c. Dept. of Biochemistry and Molecular Biology, James Cook University,
d. Centre of Excellence for Alzheimer’s Disease Research and Care, Edith Cowan
e. Zentaris GmbH, Frankfurt am Main, Germany
f. GeroNova Research, Inc., Richmond, CA, USA